Novavax has initiated a phase III study of its COVID-19 vaccine candidate in the UK, which will aim to enrol up to 10,000 volunteers. The study will evaluate the efficacy, safety and immunogenicity of the vaccine, NVX-CoV2373, in individuals aged between 18-84, with and without relevant comorbidities. The trial is being conducted in partnership with the UK government’s Vaccines Taskforce and is designed to enrol at least 25% of participants over the age of 65. It will also prioritise groups that are most affected by COVID-10, including racial and ethnic minorities. Source: Pharmatimes 25/09/2020